Butterfly Network is a digital health company that pioneered semiconductor-based, whole-body ultrasound using its proprietary Ultrasound-on-Chip technology. Its flagship devices — the iQ3, iQ+, and iQ+ Bladder — allow clinicians to perform imaging with a single handheld probe connected to a smartphone or tablet. The company pairs this hardware with cloud software and artificial intelligence, including the Compass AI enterprise workflow platform and the Butterfly Garden AI marketplace, and generates revenue through device sales, software subscriptions, and the licensing and co-development of its chip platform through the Butterfly Embedded program. Investors follow BFLY for its expansion beyond standalone devices into enterprise point-of-care ultrasound, embedded partnerships, and a planned Home & Community Care offering. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, BFLY declined approximately 24.8%, moving from a September 30 adjusted close of $8.96 to around $6.74. The move was not a straight line: shares spiked above $10 intraday in early October before steadily giving back ground through the month. Over the last quarter, the stock has traded in a wide range between roughly $6.58 and $10.21, with notable peaks in late September near $9.93 and again in early October. From its late-July level near $8.17, the current quote reflects a decline of roughly 17% to 18% over the trailing three months — a notable cooldown from a multi-month rally even as the shares remain sharply higher on a year-over-year basis.
The 30-day decline reflects a combination of profit-taking and specific concerns that outweighed otherwise strong operating results. After a rally in which the stock had appreciated substantially over the trailing year, momentum cooled as investors locked in gains. Butterfly Network reported third-quarter results in late October that beat expectations — revenue of $32.6 million, up 52% year over year, with a company-record 73% gross margin — and management raised full-year revenue guidance to $123 million to $126 million. However, the report also disclosed a new $150 million universal shelf registration and at-the-market program, which renewed dilution concerns. International revenue declined 5% year over year, core point-of-care-ultrasound revenue grew only 5%, and iQ+ sales fell 9%. Management also indicated that fourth-quarter revenue guidance implies a potential sequential decline, and investors weighed concentration risk around the large Midjourney partnership that is driving much of the Embedded segment's growth. These factors pressured the stock even as the company achieved FedRAMP authorization, opening access to U.S. federal government purchasing.
Over the last quarter, BFLY's narrative shifted from rapid appreciation toward consolidation. The preceding rally was fueled by accelerating revenue growth, improving gross margins, a narrowing adjusted EBITDA loss, and enthusiasm around the Butterfly Embedded program — particularly the Midjourney co-development partnership — as well as enterprise Compass AI software adoption and the emerging AI-imaging theme. As those gains priced in elevated expectations, the stock became more sensitive to execution details. The recent pullback reflects investors reassessing the durability of growth amid slowing core business momentum, international softness, the timing and lumpiness of Embedded revenue, and the financing-related dilution risk. Despite the retreat, the shares remain well above year-ago levels, underscoring how much optimism had been embedded in the prior run-up. From what I see, this cooldown is a natural part of digesting prior gains.
Investors will likely monitor whether Butterfly can convert its enterprise and federal opportunities into sustained revenue. Key items include fourth-quarter results against the company's implied $31 million to $34 million revenue range, the commercial launch of its first Home & Community Care state program, and the cadence and lumpiness of Embedded revenue. The 2027 product roadmap — including the next-generation P5.1-based probe, the iQ Station cart platform, and the Apollo chip program — represents a potential catalyst, as does the company's shift toward larger institutional and enterprise customers internationally. Macro factors such as tariffs, AI-driven supply-chain constraints, and competitive pressure in point-of-care ultrasound also bear watching. Finally, the recently filed at-the-market program introduces potential dilution that investors may weigh against the company's path toward cash-flow breakeven and its $122 million cash position. This information is provided for context only and is not investment advice.
In my research, I frequently turn to Tickeron AI Trading Bots to gauge how automated strategies are handling positions in volatile names like BFLY. The platform offers a useful perspective on market movements that complements my own review of fundamentals and technicals.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where BFLY declined for three days, in 285 of 320 cases, the price declined further within the following month. The odds of a continued downward trend are 89%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BFLY as a result. In 71 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for BFLY turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 37 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
BFLY moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BFLY crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.
Following a +17.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where BFLY advanced for three days, in 186 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 137 of 156 cases where BFLY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 88%.
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.559) is normal, around the industry mean (3.870). P/E Ratio (-25.897) is within average values for comparable stocks, (1.382). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (16.556) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. BFLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 64 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BFLY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalNursingServices